Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 241-793-5 | CAS number: 17832-28-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Description of key information
In a combined repeated dose toxicity study with the reproduction/developmental toxicity screening test (OECD 422; BASF SE 2010) the NOAEL for reproductive performance, fertility and for developmental toxicity is 450 mg/kg body weight/day, the highest dose tested.
No further studies available (exposure based adaptation of information requirements).
Additional information
In a combined repeated dose toxicity study with the reproduction/developmental toxicity screening test (OECD 422; BASF SE 2010) 4 -(vinyloxy)butan-1 -ol was administered orally via gavage to groups of 10 male and 10 female Wistar rats (F0 animals) at doses of 50, 150, and 450 mg/kg body weight/day. Control animals were dosed daily with the vehicle (Olive oil Ph. Eur./DAB). The duration of treatment covered a 2-week pre-mating and mating period in both sexes, approximately 1 week postmating in males, and the entire gestation period as well as 4 days of lactation in females. No adverse effects on fertility of the F0 parental animals of both sexes at dose levels of 50, 150 and 450 mg/kg bw/d were observed. The test substance caused also no impairments of the reproductive performance. Mating behaviour, conception, gestation, parturition, as well as sexual organ weights and gross and histopathological findings of these organs were not influenced. Concerning clinical pathology no treatment-related, adverse effects were observed up to a dose of 450 mg/kg bw/d. Regarding pathology there were no substance-related organ weight changes, gross lesions, or microscopic findings. Under the conditions of this study the NOAEL for reproductive performance, fertility and for developmental toxicity is 450 mg/kg body weight/day, the highest dose tested. The NOAEL for general, systemic toxicity of the test substance is 150 mg/kg body weight/day for the F0 parental animals based on adverse clinical findings (males + females) and decreased body weight gain (males) at 450 mg/kg body weight/day.
Exposure based adaptation of information requirements:
According to REGULATION (EC) No 1907/2006, Annex IX and Annex X, reproductive toxicity testing (section 8.7) may be omitted, if relevant human exposure can be excluded in accordance with Annex XI section 3. Furthermore and in accordance with section 3.2 (b) of Annex XI (as amended by Regulation 134/2009), testing for reproductive toxicity can be omitted when the substance is not incorporated in an article and the manufacturer can demonstrate and document for all relevant scenarios that throughout the life cycle strictly controlled as well as rigorously contained conditions as set out in Article 18(4)(a) to (f) (Regulation 1907/2006) apply.
Classification / toxicological profile:
4-(vinyloxy)butan-1-ol (HBVE) is classified for acute oral toxicity (cat. 4) and eye irritation (cat. 2A) according to UN GHS. The acute toxicity in rats after inhalation of saturated vapour is low. No signs of toxicity were found in rats after dermal treatment with 2000 mg/kg bw. HBVE is not sensitizing and not irritant to skin. The availablein vitrotests for genetic toxicity gave no hint on a mutagenic or clastogenic effect.
Repeated dose and reproductive toxicity was investigated in rats by the oral route (OECD 422). The NOAEL for general, systemic toxicity of the test substance was 150 mg/kg body weight/day for the parental animals based on adverse clinical findings (males + females) and decreased body weight gain (males) at 450 mg/kg body weight/day. The NOAEL for reproductive performance, fertility and for developmental toxicity was 450 mg/kg body weight/day (highest dose tested).
Process description:
At room temperature, HBVE is a liquid with low vapour pressure. The industrial method used for the production of HBVE is the reaction of acetylene with 1,4-butanediol in the presence of potassium hydroxide in the liquid phase (Reppe vinylation) under pressure and increased temperature. Working under pressure affords the acetylene to be diluted with nitrogen to avoid uncontrolled decomposition. Because of the applied reaction conditions and the handling of gaseous compounds the manufacturing facilities are designed as closed systems for higher pressures. The reaction is carried out in a stirred vessel type reactor. The alcohol/KOH-mixture is charged at the top, while the gaseous mixture of acetylene and nitrogen is fed in from below. The un-reacted acetylene is recycled to the reactor and supplemented with pure acetylene. Thus, HBVE is produced in a closed system.
Because of the significant health hazards during production (high pressure, high temperature, strong alkalinity, use of acetylene as starting material), transportation and storage (flammability, explosion, strong alkalinity), most stringent safety instructions and explosion protection measures must be adhered. Transfers, buffer/storage tanks, reactors, processing equipment and feeds are operated in fully closed systems. HBVE is practically exclusively used as an industrial intermediate for the manufacture of vinyl ether polymers and co-polymers. During manufacture and processing of HBVE, worker exposure is controlled by the use of closed systems, industrial hygiene controls, and personal protective equipment. Any risk of accumulation is minimized by natural ventilation, as the chemical is produced in closed systems installed in open air. At processing sites, the exposure of workers is minimized by vapor abstraction. Prior to repair and maintenance work, vessels, pipes and other equipment are purged to remove any residual HBVE. Dedicated systems designed to handle HBVE are used for loading and unloading purposes to prevent the formation of explosive atmospheres and to minimize exposure. The vent gases are either incinerated or cleaned by means of a scrubber. At the production and processing sites, workers wear personal protective equipment which includes gloves, face shields and safety goggles in view of the low pH during processing. During repair and maintenance operations, respiratory protective equipment is additionally used. Additionally, only a small, well-defined and trained group of workers will perform occasionally sampling tasks for quality control under strictly controlled conditions.
Consumer exposure to residual HBVE is considered to be negligible, since most of the marketed vinyl ether polymers and co-polymers are heat-treated and potentially existing residual HBVE is expected to evaporate during this process.
Rigorous containment measures:
The substance is manufactured and used under strictly controlled conditions over the entire lifecycle. Exposure is limited to occasional sampling tasks for quality control. Transport, storage tanks, reactors, processing equipment, and feeds operate in fully closed systems.
Procedural and control technologies are used to minimise residual emissions/exposure as well as qualitative risk considerations:
Operational and technical conditions and measures affecting and controlling workers exposure, such as local exhaust ventilation as well as personal protective equipment, such as goggles, chemically resistant gloves, and respiratory protection where potential exposure may occur.
On the basis of the described process conditions, testing of HBVE in a pre-natal developmental toxicity study (OECD 414) as well as a two-generation reproduction toxicity study (OECD 416) or an extended one-generation reproductive toxicity study (OECD 443) was not performed since the criteria of exposure based adaptation of information requirements are met.
Effects on developmental toxicity
Description of key information
In a combined repeated dose toxicity study with the reproduction/developmental toxicity screening test (OECD 422; BASF SE 2010), the NOAEL for reproductive performance, fertility and for developmental toxicity is 450 mg/kg body weight/day, the highest dose tested.
Additional information
In a combined repeated dose toxicity study with the reproduction/developmental toxicity screening test (OECD 422; BASF SE 2010) 4 -(vinyloxy)butan-1 -ol was administered orally via gavage to groups of 10 male and 10 female Wistar rats (F0 animals) at doses of 50, 150, and 450 mg/kg body weight/day. Control animals were dosed daily with the vehicle (Olive oil Ph. Eur./DAB). The duration of treatment covered a 2-week pre-mating and mating period in both sexes, approximately 1 week postmating in males, and the entire gestation period as well as 4 days of lactation in females. No adverse effects on fertility of the F0 parental animals of both sexes at dose levels of 50, 150 and 450 mg/kg bw/d were observed. The mean number of delivered pups per dam and the rate of liveborn and stillborn pups were evenly distributed among test groups 0 (control) and 450 mg/kg bw/d. The respective values reflect the normal range of biological variation inherent in the strain used in this study. The viability index as indicator for pup mortality between PND 0-4 varied between 99% (450 mg/kg bw/d) and 100% (test groups 0-150 mg/kg bw/d). The sex distribution and sex ratios of live F1 pups on the day of birth and on PND 4 did not show biologically relevant differences between the test groups. The F1 pups did not show any substance-induced or spontaneous clinical signs up to scheduled sacrifice on PND 4. Mean pup body weights and pup body weight changes of all substance-treated groups were comparable to the concurrent control group throughout the lactation period.
Under the conditions of this study the NOAEL for reproductive performance, fertility and for developmental toxicity is 450 mg/kg body weight/day, the highest dose tested. The NOAEL for general, systemic toxicity of the test substance is 150 mg/kg body weight/day for the F0 parental animals based on adverse clinical findings (males + females) and decreased body weight gain (males) at 450 mg/kg body weight/day.
Exposure based adaptation of information requirements:
According to REGULATION (EC) No 1907/2006, Annex IX and Annex X, reproductive toxicity testing (section 8.7) may be omitted, if relevant human exposure can be excluded in accordance with Annex XI section 3. Furthermore and in accordance with section 3.2 (b) of Annex XI (as amended by Regulation 134/2009), testing for reproductive toxicity can be omitted when the substance is not incorporated in an article and the manufacturer can demonstrate and document for all relevant scenarios that throughout the life cycle strictly controlled as well as rigorously contained conditions as set out in Article 18(4)(a) to (f) (Regulation 1907/2006) apply.
Classification / toxicological profile:
4-(vinyloxy)butan-1-ol (HBVE) is classified for acute oral toxicity (cat. 4) and eye irritation (cat. 2A) according to UN GHS. The acute toxicity in rats after inhalation of saturated vapour is low. No signs of toxicity were found in rats after dermal treatment with 2000 mg/kg bw. HBVE is not sensitizing and not irritant to skin. The availablein vitrotests for genetic toxicity gave no hint on a mutagenic or clastogenic effect.
Repeated dose and reproductive toxicity was investigated in rats by the oral route (OECD 422). The NOAEL for general, systemic toxicity of the test substance was 150 mg/kg body weight/day for the parental animals based on adverse clinical findings (males + females) and decreased body weight gain (males) at 450 mg/kg body weight/day. The NOAEL for reproductive performance, fertility and for developmental toxicity was 450 mg/kg body weight/day (highest dose tested).
Process description:
At room temperature, HBVE is a liquid with low vapour pressure. The industrial method used for the production of HBVE is the reaction of acetylene with 1,4-butanediol in the presence of potassium hydroxide in the liquid phase (Reppe vinylation) under pressure and increased temperature. Working under pressure affords the acetylene to be diluted with nitrogen to avoid uncontrolled decomposition. Because of the applied reaction conditions and the handling of gaseous compounds the manufacturing facilities are designed as closed systems for higher pressures. The reaction is carried out in a stirred vessel type reactor. The alcohol/KOH-mixture is charged at the top, while the gaseous mixture of acetylene and nitrogen is fed in from below. The un-reacted acetylene is recycled to the reactor and supplemented with pure acetylene. Thus, HBVE is produced in a closed system.
Because of the significant health hazards during production (high pressure, high temperature, strong alkalinity, use of acetylene as starting material), transportation and storage (flammability, explosion, strong alkalinity), most stringent safety instructions and explosion protection measures must be adhered. Transfers, buffer/storage tanks, reactors, processing equipment and feeds are operated in fully closed systems. HBVE is practically exclusively used as an industrial intermediate for the manufacture of vinyl ether polymers and co-polymers. During manufacture and processing of HBVE, worker exposure is controlled by the use of closed systems, industrial hygiene controls, and personal protective equipment. Any risk of accumulation is minimized by natural ventilation, as the chemical is produced in closed systems installed in open air. At processing sites, the exposure of workers is minimized by vapor abstraction. Prior to repair and maintenance work, vessels, pipes and other equipment are purged to remove any residual HBVE. Dedicated systems designed to handle HBVE are used for loading and unloading purposes to prevent the formation of explosive atmospheres and to minimize exposure. The vent gases are either incinerated or cleaned by means of a scrubber. At the production and processing sites, workers wear personal protective equipment which includes gloves, face shields and safety goggles in view of the low pH during processing. During repair and maintenance operations, respiratory protective equipment is additionally used. Additionally, only a small, well-defined and trained group of workers will perform occasionally sampling tasks for quality control under strictly controlled conditions.
Consumer exposure to residual HBVE is considered to be negligible, since most of the marketed vinyl ether polymers and co-polymers are heat-treated and potentially existing residual HBVE is expected to evaporate during this process.
Rigorous containment measures:
The substance is manufactured and used under strictly controlled conditions over the entire lifecycle. Exposure is limited to occasional sampling tasks for quality control. Transport, storage tanks, reactors, processing equipment, and feeds operate in fully closed systems.
Procedural and control technologies are used to minimise residual emissions/exposure as well as qualitative risk considerations:
Operational and technical conditions and measures affecting and controlling workers exposure, such as local exhaust ventilation as well as personal protective equipment, such as goggles, chemically resistant gloves, and respiratory protection where potential exposure may occur.
On the basis of the described process conditions, testing of HBVE in a pre-natal developmental toxicity study (OECD 414) as well as a two-generation reproduction toxicity study (OECD 416) or an extended one-generation reproductive toxicity study (OECD 443) was not performed since the criteria of exposure based adaptation of information requirements are met.
Justification for classification or non-classification
Classification is not warranted according to the criteria of EU Classification, Labelling and Packaging of Substances and Mixtures (CLP) Regulation (EC) No. 1272/2008.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.